SXTP Stock Forecast & Price Target

60 Degrees is currently facing financial challenges due to lower than expected revenue in Q1, higher operating expenses, and dilution from recent ATM sales. Their ARAKODA commercial access initiatives may offer some potential for revenue growth in the future, but the lack of visibility on regulatory approvals and potential dilution from future capital raises could lead to negative consequences for the stock. Additionally, their current financial constraints may make it difficult for them to successfully execute their clinical development plans without external support. The risk factors include balance sheet and liquidity concerns, ability to gain approvals and commercialize products, competition, and changing macroeconomic factors. However, with their focus on developing new therapies for infectious diseases and their recent submission of a regulatory filing for a new non-prescription product, the company may still have potential for filling an unmet need in the market. Overall, due to the financial constraints and lack of visibility, a neutral rating is appropriate for this stock.

60 Degrees is struggling with a low cash position, with only $3.3 million in cash at the end of Q1 and a high annual burn rate of $8 million. The decline in product revenue in Q1 is concerning, and with the recent 1:4 reverse stock split and a raise of only $2.5 million through ATM sales, it appears that the company will need more financing in the next 3-6 months to sustain their operations.